Cubic foot

Piñon Midstream Increases Delaware Basin Sour Gas Treating Capacity by ~50% and Obtains Critical NSR Permit to Continue Expansions

Retrieved on: 
水曜日, 5月 22, 2024
Oil, Gas, Energy, Dark, Hydrogen sulfide, Cubic foot, NSR, Carbon, Delaware Basin, Natural gas, CO2, Increment, Carbon dioxide, New Source Review, Dark Horse, TEG, Potash

Piñon Midstream, LLC (“Piñon”) is pleased to announce the commissioning of its third 450-GPM amine treating unit (“Amine Train III”), which is now in service at its sour natural gas treating and carbon capture facility, the Dark Horse Treating Facility (“Dark Horse”), located in Lea County, New Mexico.

Key Points: 
  • Piñon Midstream, LLC (“Piñon”) is pleased to announce the commissioning of its third 450-GPM amine treating unit (“Amine Train III”), which is now in service at its sour natural gas treating and carbon capture facility, the Dark Horse Treating Facility (“Dark Horse”), located in Lea County, New Mexico.
  • In addition, Piñon has received a critical New Source Review (“NSR”) air permit, which enables the execution of additional capital expansion projects at Dark Horse, including construction of Amine Trains IV, V and VI, as well as two cryogenic processing plants.
  • On May 8, 2024, Piñon successfully placed Amine Train III in-service at the Dark Horse Treating Facility, increasing the sour natural gas treating capacity of the facility by 50% to ~270 MMcf/d.
  • In February 2024, Piñon received a critical NSR air permit, opening the way for future growth projects at the Dark Horse Treating Facility.

4DMT Reports First Quarter 2024 Financial Results and Operational Highlights

Retrieved on: 
木曜日, 5月 9, 2024
FDA, Regenerative medicine, Research, Choroideremia, Biopsy, European Medicines Agency, Injection, Overalls, Inflammation, Food, Alpha-1 antitrypsin, Cystic fibrosis, Chelsea Handler, Intravitreal administration, Conference, Retina, Atypical hemolytic uremic syndrome, DME, Angiogenesis, PRISM, AMD, Safety, Security (finance), Cash, Retinitis pigmentosa, Exercise, PRIME, EMA, NHP, Clinical trial, A1AT, ASRS, ARVO, ECFS, Șaeș, Cubic foot, Patient, Society, Geographic atrophy, Pharmaceutical industry

“The first quarter of 2024 kicks off another transformative year for 4DMT with exceptional progress across our product pipeline and platform in multiple therapeutic areas, particularly our lead program 4D-150 in large market VEGF-driven retinal diseases,” said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT.

Key Points: 
  • “The first quarter of 2024 kicks off another transformative year for 4DMT with exceptional progress across our product pipeline and platform in multiple therapeutic areas, particularly our lead program 4D-150 in large market VEGF-driven retinal diseases,” said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT.
  • R&D Expenses: Research and development expenses were $27.9 million for the first quarter of 2024, as compared to $22.4 million for the first quarter of 2023.
  • G&A Expenses: General and administrative expenses were $10.3 million for the first quarter of 2024, as compared to $8.0 million for the first quarter of 2023.
  • Net Loss: Net loss was $32.4 million for the first quarter of 2024, as compared to net loss of $28.7 million for the first quarter of 2023.

Epsilon Reports First Quarter 2024 Results

Retrieved on: 
水曜日, 5月 8, 2024
Permian, NRI, Central Time, Investment, News, Natural gas, TILS, MMBTU, Conference, Webcast, PDP, TIL, Acquisition, Interest, Cubic foot, Oil

Epsilon’s capital expenditures were $21.4 million for the quarter ended March 31, 2024.

Key Points: 
  • Epsilon’s capital expenditures were $21.4 million for the quarter ended March 31, 2024.
  • In addition, our operating partner in PA curtailed production in response to low realized gas prices in the first quarter (quantified above).
  • The Company will host a conference call to discuss its results on Thursday, May 9, 2024 at 9:30 a.m. Central Time (10:30 a.m. Eastern Time).
  • Participants should ask to be joined to the “Epsilon Energy First Quarter 2024 Earnings Conference Call.”
    A webcast can be viewed at: https://event.choruscall.com/mediaframe/webcast.html?webcastid=BtayVC7k .

Canacol Energy Ltd. Announces New Gas Discovery at Pomelo 1

Retrieved on: 
水曜日, 3月 27, 2024
CDO, Spondias mombin, Corporation, CNE, TSX, Ciénega, Interval, Bactris gasipaes, Porosity, Cubic foot, Oil

CALGARY, Alberta, March 27, 2024 (GLOBE NEWSWIRE) -- Canacol Energy Ltd. ("Canacol" or the "Corporation") (TSX:CNE; OTCQX:CNNEF; BVC:CNEC) is pleased to provide the following information concerning the new Pomelo 1 gas discovery.

Key Points: 
  • CALGARY, Alberta, March 27, 2024 (GLOBE NEWSWIRE) -- Canacol Energy Ltd. ("Canacol" or the "Corporation") (TSX:CNE; OTCQX:CNNEF; BVC:CNEC) is pleased to provide the following information concerning the new Pomelo 1 gas discovery.
  • The well encountered 96 feet true vertical depth of net gas pay with average porosity of 21 percent within the primary Cienaga de Oro (“CDO”) sandstone reservoir.
  • The CDO reservoir was perforated over a 48-foot Interval and was tied into the existing flowline to the Betania substation.
  • The Corporation is currently mobilizing the rig to drill the Chontaduro 1 exploration well located approximately 3 kilometers to the north of Pomelo discovery.

4D Molecular Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights

Retrieved on: 
水曜日, 5月 10, 2023
PRISM, ARVO, DME, Cubic foot, AMD, Clinical trial, Fabry disease, Geographic atrophy, Diabetic retinopathy, Cash, Sale, Acquisition, Patient, Security (finance), CST, Research, Therapy, Conference, Macular degeneration, D, 3D printing, Pharmaceutical industry, Video game

We observed excellent tolerability and clinical activity in these high anti-VEGF need patients that we believe support a differentiated profile.

Key Points: 
  • We observed excellent tolerability and clinical activity in these high anti-VEGF need patients that we believe support a differentiated profile.
  • R&D Expenses: Research and development expenses were $22.4 million for the quarter ended March 31, 2023 as compared to $19.4 million for the first quarter of 2022.
  • G&A Expenses: General and administrative expenses were $8.0 million for the quarter ended March 31, 2023 as compared to $8.2 million for the first quarter of 2022.
  • Net Loss: Net loss was $28.7 million for the quarter ended March 31, 2023, as compared to $26.3 million for the first quarter of 2022.

PEI Announces 53% Increase in TPP Reserves in 2022 Reserve Report

Retrieved on: 
金曜日, 5月 5, 2023
Barrel (unit), PUD, Oil, Aircraft, FRA, Insite, TPP, Cubic foot, Oportunidades, NPV, Corporation, PEI, OTC, Solarmer Energy, Inc., WCS

In 2022, two horizontal re-entry pilot wells were drilled to assess the technical and economic merits to substantiate a full scale development program.

Key Points: 
  • In 2022, two horizontal re-entry pilot wells were drilled to assess the technical and economic merits to substantiate a full scale development program.
  • The PEI pilots enabled reserves booking of 100 Mbbl TPP reserves per horizontal well, additional PUD locations with total proved (TP) reserves of 1.8 MMbbl and total proved plus probable (TPP) reserves of 2.2 MMbbl.
  • Prospera also exploited uphole zones in these fields with five new recompletions accessing new reserves of 128 Mbbl and 837 MMcf TPP reserves with significant development upside to add new production and reserves.
  • These wells will access new pool reserves and provide PEI with new incremental medium oil production, improving corporate production and margin.

Aevitas Therapeutics, a Fortress Biotech Subsidiary, Announces Asset Purchase Agreement with 4D Molecular Therapeutics for World-Wide Rights to Aevitas’ Short-Form Human Complement Factor H

Retrieved on: 
月曜日, 4月 24, 2023
Fortress Biotech, Perelman School of Medicine at the University of Pennsylvania, CFH, University, Fortification, Cubic foot, Complement, Geographic atrophy, Factor, University of Pennsylvania, GA, AAV, Patient, Ophthalmology, Therapy, Vaccine, Pharmacology

MIAMI, April 24, 2023 (GLOBE NEWSWIRE) -- Aevitas Therapeutics, Inc. (“Aevitas”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) subsidiary company, and 4D Molecular Therapeutics (Nasdaq: FDMT) (“4DMT”), a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic medicines targeting large-market diseases, today announced the execution of an asset purchase agreement for 4DMT to acquire Aevitas’ proprietary rights to its short-form human complement factor H (“sCFH”) asset for the treatment of complement-mediated diseases.

Key Points: 
  • MIAMI, April 24, 2023 (GLOBE NEWSWIRE) -- Aevitas Therapeutics, Inc. (“Aevitas”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) subsidiary company, and 4D Molecular Therapeutics (Nasdaq: FDMT) (“4DMT”), a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic medicines targeting large-market diseases, today announced the execution of an asset purchase agreement for 4DMT to acquire Aevitas’ proprietary rights to its short-form human complement factor H (“sCFH”) asset for the treatment of complement-mediated diseases.
  • Under the terms of the agreement, 4DMT will make cash payments to Aevitas totaling up to ~$140 million in potential late-stage development, regulatory and sales milestones.
  • A range of single-digit royalties on net sales are also payable.
  • Partnering with 4DMT further validates the Fortress business model of identifying and developing promising treatments for patients, while pursuing opportunities that potentially maximize shareholder value.

4DMT Acquires Complement Pathway Inhibitor Payload for 4D-175 Product Candidate for Geographic Atrophy

Retrieved on: 
月曜日, 4月 24, 2023
Retina, Injection, Perelman School of Medicine at the University of Pennsylvania, CFH, University, Chelsea Handler, Doctor of Philosophy, Attention deficit hyperactivity disorder predominantly inattentive, AMD, Cubic foot, Inflammation, CMC, Survival, Complement, End organ damage, Factor, University of Pennsylvania, Atypical hemolytic uremic syndrome, GA, AAV, Geographic atrophy, IVT, Patient, Ophthalmology, Therapy, Autoimmunity, Disease, Vaccine, Pharmaceutical industry, R100, Pharmacology

Geographic atrophy is a highly prevalent disease with a significant unmet medical need.

Key Points: 
  • Geographic atrophy is a highly prevalent disease with a significant unmet medical need.
  • According to published estimates, there are over one million individuals with GA in the U.S. alone as of 2022.
  • The first treatment for GA, complement inhibitor pegcetacoplan injection, was approved in the U.S. in February 2023 and is administered by intravitreal (IVT) injection once every 25 to 60 days.
  • Complement Factor H (CFH) is a master regulator of the complement system, functioning as a natural inhibitor of the alternative complement pathway.

TRILLION ENERGY RECEIVES DECEMBER GAS REVENUES FOR SASB

Retrieved on: 
水曜日, 1月 25, 2023
Akçakoca, Cubic foot, USD, CSE

Vancouver, B.C., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Trillion Energy International Inc. (“Trillion” or the “Company”) (CSE: TCF) (OTCQB: TRLEF) (Frankfurt: Z62).

Key Points: 
  • Vancouver, B.C., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Trillion Energy International Inc. (“Trillion” or the “Company”) (CSE: TCF) (OTCQB: TRLEF) (Frankfurt: Z62).
  • Trillion is pleased to provide an update on revenue receipts and production data from SASB for the month of December 2022 for the two new producing wells.
  • Trillion’s 49% share of December 2022 gas production (net of utility gas volumes) was 87.4 MMcf, generating USD $2,647,053 before royalties (US $2,342,633 after royalties) net to the Company.
  • “As per our plan, the gas revenues generated are being used to fund further drilling activities at SASB.

Canacol Energy Ltd. Provides Update on Gas Sales and Drilling Programs

Retrieved on: 
月曜日, 10月 3, 2022
Maintenance, Toronto Stock Exchange, E&P, CNE, Negotiation, Alboka, GAS, TVD, Ciénega, Corporation, VMM, CDO, Risk, Cubic foot, OTCQX, Colombia Stock Exchange, Acquisition, Forward-looking statement, Manjar blanco, TSX, GLOBE, Oil, Atlantic Ocean

Realized contractual natural gas sales (which are gas produced, delivered, and paid for) were 166 million standard cubic feet per day (MMscfpd) for August 2022, and 191 MMscfpd for September 2022.

Key Points: 
  • Realized contractual natural gas sales (which are gas produced, delivered, and paid for) were 166 million standard cubic feet per day (MMscfpd) for August 2022, and 191 MMscfpd for September 2022.
  • This, coupled with high reservoir levels due to intense rains, temporarily reduced interruptible gas sales which recovered to normal levels in September.
  • The Corporation completed the drilling of the Canaflecha 2 well located on the Esperanza Block, operated by CNE OIL & GAS S.A.S.
  • Realized contractual gas sales is defined as gas produced and sold plus gas revenues received from nominated take or pay contracts.